Biology of Blood and Marrow Transplantation
Volume 12, Issue 2 , Pages 217-225 , February 2006

Tacrolimus and Mycophenolate Mofetil after Nonmyeloablative Matched-Sibling Donor Allogeneic Stem-Cell Transplantations Conditioned with Fludarabine and Low-Dose Total Body Irradiation

  • Yago Nieto

      Affiliations

    • Bone Marrow Transplant Programs, University of Navarra, Pamplona, Spain
    • Corresponding Author InformationCorrespondence and reprint requests: Yago Nieto, MD, Clínica Universitaria de Navarra, Avda Pío XII-36, Pamplona 31080, Spain
    • ,
  • Nigel Patton

      Affiliations

    • Canterbury Health Laboratories, Christchurch, New Zealand
    • ,
  • Timothy Hawkins

      Affiliations

    • Auckland City Hospital, Auckland, New Zealand
    • ,
  • Ruth Spearing

      Affiliations

    • Canterbury Health Laboratories, Christchurch, New Zealand
    • ,
  • Scott I. Bearman

      Affiliations

    • Rocky Mountain Cancer Center, Denver, Colorado
    • ,
  • Roy B. Jones

      Affiliations

    • M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Elizabeth J. Shpall

      Affiliations

    • M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Rachel Rabinovitch

      Affiliations

    • Department of Radiation Oncology, University of Colorado
    • ,
  • Chan Zeng

      Affiliations

    • Department of Biostatistics, University of Colorado
    • ,
  • Anna Barón

      Affiliations

    • Department of Biostatistics, University of Colorado
    • ,
  • Peter A. McSweeney

      Affiliations

    • Rocky Mountain Cancer Center, Denver, Colorado

Received 7 September 2005 ,Accepted 6 October 2005.

References 

  1. Giralt S , Estey E , Albitar M , et al.   Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy (harnessing graft-versus-leukemia without myeloablative therapy) . Blood . 1997;89:4531–4536
  2. Khouri IF , Keating M , Korbling M , et al.   Transplant-lite (induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies) . J Clin Oncol . 1998;16:2817–2824
  3. Slavin S , Nagler A , Naparstek E , et al.   Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases . Blood . 1998;91:756–763
  4. Sykes M , Preffer F , McAfee S , et al.   Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation . Lancet . 1999;353:1755–1759
  5. Childs R , Clave E , Contentin N , et al.   Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation (full donor T-cell chimerism precedes alloimmune responses) . Blood . 1999;94:3234–3241
  6. Chakraverty R , Peggs K , Chopra R , et al.   Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen . Blood . 2002;99:1071–1078
  7. McSweeney PA , Niederwieser D , Shizuru JA , et al.   Hematopoietic cell transplantation in older patients with hematologic malignancies (replacing high-dose cytotoxic therapy with graft-versus-tumor effects) . Blood . 2001;97:3390–3400
  8. Niederwieser D , Maris M , Shizuru JA , et al.   Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases . Blood . 2003;101:1620–1629
  9. Diaconescu R , Flowers CR , Storer B , et al.   Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors . Blood . 2004;104:1550–1558
  10. Sorror ML , Maris MB , Storer B , et al.   Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning (influence of pretransplant comorbidities) . Blood . 2004;104:961–968
  11. Mielcarek M , Martin PJ , Leisenring W , et al.   Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation . Blood . 2003;102:756–762
  12. Kino T , Hatanaka H , Miyata S , et al.   FK506, a novel immunosuppressant isolated from a Steptomyces. II (Immunosuppressive effects of FK506 in vitro) . J Antibiot . 1987;40:1256–1265
  13. Ratanatharathorn V , Nash RA , Przepiorka D , et al.   Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation . Blood . 1998;92:2303–2314
  14. Nash RA , Antin JH , Karanes C , et al.   Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors . Blood . 2000;96:2062–2068
  15. Tanabe M , Todo S , Murase N , et al.   Therapeutic synergism between low-dose FK506 and antimetabolites in rat allogeneic heart transplantation . Transplant Proc . 1995;27:364–365
  16. Zucker K , Rosen A , Tsaroucha A , et al.   Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings . Transplant Immunol . 1997;5:225–232
  17. Gregoor S , de Sevaux R , Hene R , et al.   Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients . Transplantation . 1999;68:1603–1606
  18. Van Gelder T , Klupp J , Barten MJ , et al.   Co-administration of tacrolimus and mycophenolate mofetil does not increase mycophenolic acid (MPA) exposure, but co-administration of cyclosporine inhibits the enterohepatic recirculation of MPA, thereby decreasing its exposure . J Heart Lung Transplant . 2001;20:160–161
  19. Przepiorka D , Weisdorf D , Martin P , et al.   Consensus conference on acute GVHD grading . Bone Marrow Transplant . 1995;15:825–828
  20. Sullivan KM , Agura E , Anasetti C , et al.   Chronic graft-versus-host disease and other late complications of bone marrow transplantation . Semin Hematol . 1991;18:250–259
  21. Flowers MED , Traina F , Storer B , et al.   Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning . Bone Marrow Transplant . 2005;35:277–282
  22. Centers for Disease Control and Prevention, Infectious Disease Society of America, American Society of Blood and Marrow Transplantation . Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients . MMWR Recomm Rep . 2000;49:1–125 RR-10
  23. Kaplan EL , Meier P . Nonparametric estimation from incomplete observations . JAMA . 1958;53:457–481
  24. Mielcarek M , Burroughs L , Leisenring W , et al.   Prognostic relevance of “early-onset” graft-versus-host disease following non-myeloablative haematopoietic cell transplantation . Br J Haematol . 2005;129:381–391
  25. Baron F , Maris MB , Sandmaier BM , et al.   Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning . J Clin Oncol . 2005;23:1993–2003
  26. Nieto Y , Russ P , Everson G , et al.   Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation . Bone Marrow Transplant . 2000;26:109–111
  27. Junghanss C , Boeckh M , Carter RA , et al.   Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study . Blood . 2002;99:1978–1985
  28. Fukuda T , Boeckh M , Carter RA , et al.   Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning . Blood . 2003;102:827–833
  29. Burroughs L , Leisenring W , Maloney DG , et al.   Extending postgrafting cyclosporine does not decrease the risk of graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation . [abstract] Blood . 2003;102a
  30. McSweeney PA , Abhyankar S , Foran J , et al.   Favorable early transplant outcomes using tacrolimus and mycophenolate mofetil for GVHD prevention after matched sibling allografting . [abstract] Blood . 2003;102:714a

PII: S1083-8791(05)00682-8

doi: 10.1016/j.bbmt.2005.10.012

Biology of Blood and Marrow Transplantation
Volume 12, Issue 2 , Pages 217-225 , February 2006

Article Tools

* Image Usage & Resolution